Which chemo has the highest emetogenic potential?
Hint: You can sort the table by clicking on the boxes containing arrows at the top of each column.
| Drug | NCCN emetogenic potential (2021) | MASCC/ESMO emetogenic potential (2019) |
|---|---|---|
| Azacitidine (Vidaza) | Moderate | Moderate |
| Bendamustine | Moderate | Moderate |
| Belinostat (Beleodaq) | Low | |
| Bevacizumab (Avastin) | Minimal | Minimal |
Which anticancer drug has high emetogenic potential?
Table 2
| Emetogenic potential | Cytotoxic drug |
|---|---|
| High | Cisplatin |
| Cyclophosphamide | |
| Dacarbazine | |
| Mechloretamine |
Is Folfirinox highly emetogenic?
‡ At many institutions, regimens that combine oxaliplatin with irinotecan on day 1 are considered highly emetogenic, warranting the use of a neurokinin-1 receptor antagonist on day 1. The National Comprehensive Cancer Network considers this and similar regimens as moderately emetogenic.
Which chemotherapy agent has the lowest emetogenic potential?
Drugs considered to have low emetogenic risk (10%-30%) include the taxanes, etoposide, and biologics such as trastuzumab (Herceptin) and cetuximab (Erbitux). Some antineoplastic agents such as the vinca alkaloids as a class or bevacizumab (Avastin) are associated with minimal risk of emesis without prophylaxis (< 10%).
Is R chop highly emetogenic?
The CHOP regimen is the standard treatment for non-Hodgkin’s lymphoma (NHL) and is categorized as highly or moderately emetogenic in the CINV guidelines.
Which of the following anticancer drug has high emetogenic potential nausea and vomiting?
Irinotecan-based chemotherapy regimens have high emetogenic potential and require optimized antiemetic prophylactic therapy, according to a study published in Supportive Care in Cancer. Chemotherapy-induced nausea and vomiting (CINV) is one of the biggest challenges faced during anticancer treatment.
What does emetogenic mean?
Listen to pronunciation. (eh-MEH-toh-JEH-nik) Describes a substance that causes vomiting. Also called emetic.
Which chemotherapy agent S is are associated with a low 10% to 30 %) incidence of nausea and vomiting?
Is carboplatin highly emetogenic?
The NCCN has recently reclassified carboplatin emetogenicity according to the AUC (target area under the concentration versus time curve) with a carboplatin AUC ≥4 classified as highly emetogenic and carboplatin AUC < 4 as moderately emetogenic – but highly emetogenic in certain patients.